Outlook Therapeutics (OTLK – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Douglas ...
Outlook Therapeutics (OTLK) has completed the analysis of the complete 12-week safety and efficacy results for NORSE EIGHT, the second of two clinical trials evaluating ONS-5010 in wet age-related ...